{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005333","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.780311+00:00","generated_at":"2026-06-18T22:12:32.061821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aurinia Q4 2022 net revenue $28.4M (+21% YoY); FY net revenue $134.0M (+194% YoY); net loss $0.18/share","bullets":["Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.","Net loss Q4 $26.0M ($0.18/share); FY net loss $108.2M ($0.76/share).","Cash, equivalents and investments $389.4M at Dec 31, 2022.","FY 2023 net product revenue guidance reiterated at $120-140M.","Approx. 1,525 patients on LUPKYNIS therapy at year-end; 274 PSFs secured through Feb 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005333","json":"https://secwatch.observer/filing/0001628280-23-005333.json","markdown":"https://secwatch.observer/filing/0001628280-23-005333.md","text":"https://secwatch.observer/filing/0001628280-23-005333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/0001628280-23-005333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/auph-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:12:32.061821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b71cd9e48ddeda3afdebb0b81f43cb1e13e28b0","claim":"Aurinia Pharmaceuticals Inc. reported the quarter and year ended December 31, 2022 results: revenue $28.4 million. Guidance reaffirmed.","evidence_excerpt":"filing. --- EX-99.1 (EX-99.1 PRESS RELEASE) --- PRESS RELEASE Document Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/0001628280-23-005333-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$28.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}